PA
AMRX icon

Paralel Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Paralel Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Buy
+185,831
New +$2.55M 0.12% 35

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Paralel Advisors's AMRX Position: Q2 2026 in Review

Paralel Advisors opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 185,831 shares worth $3.22M. The stake represents 0.12% of the portfolio and ranks #35 among its holdings.

306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Paralel Advisors held 185,831 shares of Amneal Pharmaceuticals worth $3.22M as of Q2 2026.
  • Amneal Pharmaceuticals was a new Paralel Advisors position in Q2 2026.
  • Amneal Pharmaceuticals made up 0.12% of Paralel Advisors's portfolio in Q2 2026, its #35 holding.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Paralel Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.